Axe Compute Inc. is focused on artificial intelligence (AI) compute accessible to all through its access to the Aethir network. By delivering Aethir-provided decentralized global infrastructure, the Company will endeavor to deliver instant access to bare-metal GPUs at scale to innovators and established businesses alike. Dedicated GPU clusters delivered in 48 hours across 200+ locations. It offers Zero Virtualization Overhead, Purpose-Built for AI Workloads, Flat Rate, Zero Egress Fees, and Enterprise-Grade Support and SLAs. It provides 100% bare-metal access.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	7.66Cr 6.7Cr 6.18Cr 5.71Cr 11Cr 730.36Cr 11Cr 74Cr 29Cr 359.8Cr 29Cr 28Cr 1.24TCr	P/E 2024	-0.35x	P/E 2025	-0.53x
Enterprise Value	6.75Cr 5.9Cr 5.44Cr 5.03Cr 9.54Cr 643.33Cr 9.7Cr 65Cr 26Cr 316.93Cr 25Cr 25Cr 1.09TCr	EV / Sales 2024	4.23x	EV / Sales 2025	121x
Free-Float	93.75%	Yield 2024 *	-	Yield 2025	-

29/06	Axe Compute Inc.(NasdaqCM:AGPU) added to Russell Microcap Value Benchmark Index	CI
29/06	Axe Compute Inc.(NasdaqCM:AGPU) added to Russell 3000E Index	CI
29/06	Axe Compute Inc.(NasdaqCM:AGPU) added to Russell 3000E Value Benchmark	CI
29/06	Axe Compute Inc.(NasdaqCM:AGPU) added to Russell Microcap Index	CI
16/06	Axe Compute Inc. Secures $25.9 Million in Contracts for Long-Term Deployments of Blackwell and Grace Blackwell Compute	CI
10/06	Axe Compute Files $1 Billion Mixed Shelf	MT
27/05	Axe Compute Inc. Receives $43 Million Payment for Landmark Contract	CI
18/05	Axe Compute Inc., Q1 2026 Earnings Call, May 18, 2026
16/05	Axe Compute Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
22/04	Top Midday Gainers	MT
22/04	Axe Compute Receives $260 Million Contract to Provide Nvidia B300 Chips; Shares Jump Pre-Bell	MT
22/04	Axe Compute Inc Secures $260 Million Three-Year Enterprise Contract for 2,304-GPU NVIDIA B300 Deployment	CI
20/04	Axe Compute Inc Announces Strategic Compute Reserve Dashboard Launch	CI

15/24/15	HC Wainwright Downgrades Predictive Oncology to Neutral From Buy	MT
30/21/30	PREDICTIVE ONCOLOGY : HC Wainwright Starts Predictive Oncology at Buy With $5 Price Target	MT

07/07	Axe Compute Inc. Joins Russell Microcap® Index, Reflecting Its Growth as a Publicly Traded AI Infrastructure Platform	AQ
16/06	Axe Compute Secures $25.9 Million in Contracts for Long-Term Deployments of Blackwell and Grace Blackwell Compute	AQ
27/05	Axe Compute Receives $43M Payment for Landmark Contract	AQ
16/05	Axe Compute Inc. Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
11/05	Axe Compute to Host Q1 2026 Financial Results Conference Call	AQ

17/21/17	MÄRKTE USA/Wall Street mit Fed-Sitzung in Lauerstellung
16/21/16	New Fortress Energy : MÄRKTE USA/Wall Street mit Fed-Sitzung uneinheitlich
16/21/16	New Fortress Energy : MÄRKTE USA/S&P-500 mit Rekordhoch trotz enttäuschender US-Daten
16/21/16	New Fortress Energy : MÄRKTE USA/Wenig verändert - US-Daten liefern gemischtes Bild
16/21/16	New Fortress Energy : MARKT USA/Wenig verändert - US-Daten könnten Impulse liefern

Precision Therapeutics Inc Share Price Nasdaq

Stocks

US74033P1003

Biotechnology & Medical Research

Valuation: Precision Therapeutics Inc

Latest news : Precision Therapeutics Inc

Last Transcript: Precision Therapeutics Inc

Analysts' recommendations: Precision Therapeutics Inc

Press Releases: Precision Therapeutics Inc

News in other languages: Precision Therapeutics Inc

Quotes and Performance

Managers and Directors: Precision Therapeutics Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
Christopher Miglino CEO	Chief Executive Officer	57	09/02/2026
Jeremy Yaukey-Witter DFI	Director of Finance/CFO	-	16/04/2026
Kyle Okamoto PSD	President	-	01/04/2026

Director	Title	Age	Since
Daniel Handley BRD	Director/Board Member	66	19/02/2020
Charles L. Nuzum CHM	Chairman	78	09/02/2026
Gregory St. Clair BRD	Director/Board Member	60	09/07/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PRECISION THERAPEUTICS INC	-7.56%	-8.33%	-	-	7.66Cr
LONZA GROUP AG	+0.58%	+2.06%	+3.90%	+10.40%	5.07TCr
REVOLUTION MEDICINES, INC.	-2.22%	-1.25%	+391.53%	+591.38%	3.97TCr
IQVIA HOLDINGS INC.	-0.54%	+0.39%	+27.67%	-3.89%	3.47TCr
BEONE MEDICINES AG	-1.36%	+0.35%	+19.34%	+58.83%	3.32TCr
CELLTRION, INC.	+1.21%	-4.58%	+3.00%	+37.03%	2.68TCr
ASCENDIS PHARMA A/S	-1.81%	-1.48%	-	-	1.68TCr
MEDPACE HOLDINGS, INC.	+0.51%	-3.47%	+66.38%	+125.61%	1.54TCr
EUROFINS SCIENTIFIC SE	+0.23%	-0.58%	+13.80%	+19.56%	1.38TCr
ICON PUBLIC LIMITED COMPANY	-0.62%	-3.09%	+11.43%	-29.93%	1.28TCr
Average	-1.16%	-0.83%	+67.13%	+101.12%	2.71TCr
Weighted average by Cap.	-0.48%	-0.23%	+82.75%	+126.14%

	2024	2025
Net sales	16.24L 14.2L 13.1L 12.1L 22.96L 15Cr 23.35L 1.57Cr 61.47L 7.63Cr 60.97L 59.64L 26Cr	1L 1L 1L 93.36T 2L 1.19Cr 2L 12.08L 5L 58.86L 5L 5L 2.02Cr
Net income	-1.27Cr -1.11Cr -1.02Cr -94.37L -1.79Cr -120.79Cr -1.82Cr -12Cr -4.79Cr -60Cr -4.76Cr -4.65Cr -204.56Cr	-23Cr -20Cr -19Cr -17Cr -33Cr -2.22TCr -34Cr -224.7Cr -88Cr -1.1TCr -88Cr -86Cr -3.77TCr
Net Debt	13.96L 12.21L 11.27L 10.4L 19.74L 13Cr 20.07L 1.35Cr 52.86L 6.56Cr 52.43L 51.29L 23Cr	-91.25L -79.81L -73.62L -67.99L -1.29Cr -87Cr -1.31Cr -8.8Cr -3.45Cr -43Cr -3.43Cr -3.35Cr -147.38Cr